Alyeska Investment Group, L.P. - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 178 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.

Quarter-by-quarter ownership
Alyeska Investment Group, L.P. ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$6,860,253
+185.1%
131,700
+246.6%
0.05%
+161.1%
Q2 2023$2,406,160
-11.1%
38,000
-24.0%
0.02%
-25.0%
Q1 2023$2,707,500
-61.0%
50,000
-77.1%
0.02%
-75.5%
Q4 2020$6,947,000
-51.3%
218,473
-60.7%
0.10%
-54.8%
Q3 2020$14,275,000
+107.2%
556,312
+107.3%
0.22%
+108.7%
Q2 2020$6,890,000
-6.1%
268,400
-43.8%
0.10%
-28.8%
Q1 2020$7,338,000
-15.3%
477,426
-13.0%
0.15%
+124.6%
Q3 2017$8,663,000
+332.7%
548,955
+997.9%
0.06%
+182.6%
Q3 2015$2,002,000
+150.2%
50,000
+99.8%
0.02%
+360.0%
Q2 2015$800,000
+77.0%
25,030
+32.4%
0.01%
-16.7%
Q1 2015$452,000
-55.7%
18,908
-67.3%
0.01%
-64.7%
Q4 2014$1,021,000
+24.1%
57,853
-3.6%
0.02%0.0%
Q3 2014$823,000
-61.1%
59,995
-52.2%
0.02%
-63.8%
Q2 2014$2,116,000
-40.2%
125,493
-35.5%
0.05%
-51.5%
Q1 2014$3,537,000194,5630.10%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q4 2020
NameSharesValueWeighting ↓
TANG CAPITAL MANAGEMENT LLC 700,000$42,833,0008.57%
SILVERARC CAPITAL MANAGEMENT, LLC 308,819$18,897,0007.82%
Vahanian & Associates Financial Planning Inc. 45,533$2,786,0006.44%
DCF Advisers, LLC 238,500$14,594,0006.39%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 50,956$20,930,0004.72%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,531,923$93,738,0002.86%
Nicholas Investment Partners, LP 562,373$34,412,0002.45%
Bellevue Group AG 3,429,619$209,859,0002.44%
WASATCH ADVISORS LP 7,477,868$457,571,0002.25%
Quantum Private Wealth, LLC 73,772$4,514,0001.95%
View complete list of INTRA CELLULAR THERAPIES INC shareholders